Department of Radiation Oncology, State University of New York - Downstate, Brooklyn, NY 11203, USA.
Radiother Oncol. 2010 Jun;95(3):321-6. doi: 10.1016/j.radonc.2010.04.007. Epub 2010 May 5.
Using a population-based database, we sought to characterize brainstem gliomas and to evaluate the prognosis of various subgroups.
Using the Surveillance Epidemiology and End-Results (SEER) database we identified patients diagnosed with malignant infratentorial gliomas between 1988 and 2003 who underwent a surgical procedure and/or received radiation therapy (RT).
A total of 455 patients were identified with a median age at diagnosis of 13 years (range 0-87). The overwhelming majority, 95.6%, received RT. Median survival (MS) was 11 months. Those not undergoing RT had a MS of 3 months. MS varied significantly by age, p<0.001. MS for patients aged 0-18 years was 11 months; 19-29 years was 35 months; 30-49 years was 17 months; 50-69 years was 6 months; and 70 years or older was 3 months. The small group with grades I and II tumors had improved MS of 58 and 37 months, respectively. There was no difference in survival by the year of diagnosis (1999 versus 2000 or later) with MS of 10 versus 11 months, respectively, p=0.949.
Brainstem glioma is primarily a childhood malignancy with a generally poor prognosis. A minority of patients has favorable features and can achieve long-term survival.
利用基于人群的数据库，我们旨在描述脑桥胶质瘤的特征，并评估各亚组的预后。
我们使用监测、流行病学和最终结果（SEER）数据库，确定了 1988 年至 2003 年间诊断为恶性小脑幕下胶质瘤并接受手术和/或放射治疗（RT）的患者。
共确定了 455 例患者，中位诊断年龄为 13 岁（范围 0-87 岁）。绝大多数患者（95.6%）接受了 RT。中位总生存期（MS）为 11 个月。未接受 RT 的患者 MS 为 3 个月。年龄对 MS 有显著影响，p<0.001。0-18 岁患者的 MS 为 11 个月；19-29 岁为 35 个月；30-49 岁为 17 个月；50-69 岁为 6 个月；70 岁及以上为 3 个月。I 级和 II 级肿瘤的小患者组分别具有改善的 MS，分别为 58 个月和 37 个月。诊断年份（1999 年与 2000 年或以后）对生存没有影响，MS 分别为 10 个月和 11 个月，p=0.949。
脑桥胶质瘤主要是一种儿童期恶性肿瘤，预后一般较差。少数患者具有良好的特征，可以实现长期生存。
